Drug Profile
Research programme: diabetes therapy - Sanwa Kagaku Kenkyusho/VistaGen Therapeutics
Alternative Names: Diabetes therapy research programme - Sanwa Kagaku Kenkyusho/VistaGen TherapeuticsLatest Information Update: 21 Jul 2010
Price :
$50
*
At a glance
- Originator Sanwa Kagaku Kenkyusho; VistaGen Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 21 Jul 2010 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
- 21 Jul 2010 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 18 Jan 2005 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route)